Jagiellonian University Repository

The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma : ten questions

Communities & Collections

pcg.skipToMenu

The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma : ten questions

Show full item record

dc.contributor.author Jurczak, Wojciech [SAP20001014] pl
dc.contributor.author Długosz-Danecka, Monika [SAP20014955] pl
dc.contributor.author Rivas Navarro, Fernando pl
dc.date.accessioned 2020-01-17T10:01:36Z
dc.date.available 2020-01-17T10:01:36Z
dc.date.issued 2019 pl
dc.identifier.issn 1479-6694 pl
dc.identifier.uri https://ruj.uj.edu.pl/xmlui/handle/item/144300
dc.language eng pl
dc.rights Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/pl/legalcode *
dc.title The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma : ten questions pl
dc.type JournalArticle pl
dc.description.physical 305-317 pl
dc.abstract.en Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone immunochemotherapy remains standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). High-dose chemotherapy and stem cell transplantation is offered to most relapsing/refractory patients who respond to salvage therapy. This Q&A review evaluates recommended management strategies for second and subsequent lines of therapy in patients with DLBCL, outlining the relative efficacies of currently available options including novel agents such as ibrutinib and CAR-T cells. The combination of pixantrone and rituximab is currently under investigation as a second-line treatment for patients ineligible for stem cell transplantation, while pixantrone monotherapy is the only therapeutic option approved for multiply relapsed and refractory DLBCL beyond the second line at this time. pl
dc.subject.en CAR-T cells pl
dc.subject.en diffuse large B-cell lymphoma pl
dc.subject.en ibrutinib pl
dc.subject.en pixantrone pl
dc.subject.en salvage therapy pl
dc.subject.en second-line treatment pl
dc.description.volume 15 pl
dc.description.number 3 pl
dc.description.points 70 pl
dc.identifier.doi 10.2217/fon-2018-0388 pl
dc.identifier.eissn 1744-8301 pl
dc.title.journal Future Oncology pl
dc.language.container eng pl
dc.affiliation Wydział Lekarski : Klinika Hematologii pl
dc.subtype ReviewArticle pl
dc.rights.original CC-BY-NC-ND; inne; ostateczna wersja wydawcy; w momencie opublikowania; 0 pl
dc.identifier.project ROD UJ / OP pl
dc.cm.id 91323
dc.cm.date 2020-01-07
.pointsMNiSW [2019 A]: 70


Files in this item

Name: jurczak_dlugosz-d ...
Size: 2.473Mb
Format: PDF
View/Open
Icon
Name: jurczak_dlugosz-d ...
Size: 2.473Mb
Format: OpenOffice Writer
View/Open

This item appears in the following Collection(s)

Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa